| CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures (MILV.pk), has entered into the $8.4 billion market chronic obstructive pulmonary disease market (COPD) with the completed acquisition of a ground breaking Breathing Formula. This all natural, non-synthetic, medicine was developed for the treatment of COPD, the two most common forms of which are Emphysema and Chronic Bronchitis. We believe that there is no other product currently availabl...continued MILV |
Friday, October 28, 2011
Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment